Blank Peptides
Two-Lab Verified, Owner-Disclosed Q&A
Verdict
Wyoming-registered DTC brand with the main role of business operating out of Texas. Additional operating arms are domestic, including a cGMP-compliant lab in which the owner holds an equity stake. Dual-sourced API model: one supplier in China since late 2024 and one in India since early 2025, both FDA- and/or WHO-registered or inspected, with every inbound lot quarantined pending COA review, visual inspection, and independent retest. Two named third-party labs disclosed: Freedom Diagnostics (publicly verifiable via FreedomDiagnosticsTesting.com) and Horizon Analytical. Universal HPLC + UV + Mass Spec + USP <85> endotoxin (duplicate per batch) on every product, with specific per-batch purity values published (Retatrutide Lot 665394 at 99.887% purity, 10.01mg verified on a 10mg label). Owner has voluntarily reframed marketing from "Made in USA" to "Vialed, finished, tested, and shipped in USA", and publishes a 50-question transparency Q&A (VendorView) that openly discloses a September 2025 MOTS-C fill-volume QC failure (65% labeled potency) caught by internal QC and Freedom Diag retest before any vials shipped, including the root cause (pre-lyo fill drift on liquid filler), corrective action (tubing replaced, pump re-qualified, replacement schedule changed from calendar to cycle/volume-based). Owner self-reports 500+ unique customers on the Blank brand and roughly 10,000 across prior B2B entities (unverified externally).
Documented strengths
- Two named third-party labs disclosed: Freedom Diagnostics (publicly verifiable lookup) and Horizon Analytical
- Universal HPLC + UV + Mass Spec + USP <85> endotoxin (duplicate) on every batch
- Specific per-batch purity values published (Retatrutide Lot 665394 at 99.887%) rather than generic "99%+"
- Near-perfect fill accuracy on verified batch (10.01mg measured on 10mg label)
- Equity-stake in a domestic cGMP-compliant lab with additional domestic partner labs as backup
- Dual-sourced API model: FDA- and/or WHO-registered or inspected suppliers in China (since late 2024) and India (since early 2025); first lot from any new supplier sent to 3P lab before any commercial order
- Every inbound lot quarantined pending COA review, visual inspection, and independent retest; new suppliers and high-volume SKUs retested every lot
- Backend per-vial traceability to supplier, API lot, and synthesis date for targeted recall/notification
- 3 of "dozens" of inbound API lots rejected (below 99% purity), destroyed or returned and replaced by manufacturer
- Voluntarily disclosed September 2025 MOTS-C 65% potency QC failure with full root cause and corrective action; batch caught internally and never reached customers
- 50-question public transparency Q&A (VendorView) with verbatim owner answers, including admitted mistakes
- Honest "Vialed, finished, tested, and shipped in USA" reframe instead of "Made in USA"
- Owner openly invites anonymous independent third-party testing
- Guarantee refunds both the cost of the buyer's independent test AND the order if the product fails to match label
- Same-day 3 PM CST shipping cutoff, ~3-day average UPS Ground/Expedited delivery, free over $200
- 25-minute average email/phone response during CDT business hours; ~1 hour average after hours
- Broad payment options with buyer protection: all major credit cards, PayPal Standard, PayPal F&F, Venmo, plus a 5% discount on Zelle
- Wholesale, white-label, and drop-ship offerings to med spas, clinics, and primary-care providers signal a legitimate B2B operation underneath the DTC brand
Considerations
- No heavy metals (ICP-MS), sterility (USP <71>), residual solvents (GC-MS), or Karl Fischer water-content testing — owner acknowledges these as gaps and has roadmapped them via Horizon Analytical
- No multi-vial conformity testing yet (owner: "we need to start")
- COAs are not currently matchable to specific vials on the label (acknowledged design choice; owner considering changing for traceability)
- Owner identity not publicly disclosed; full name and exact role kept private except with wholesale customers
- Both API suppliers (one in China, one in India) named only by region, not identity
- A prior B2B entity associated with the same owner is intentionally undisclosed
- Wyoming legal registration is a tax/anonymity posture, no public street address disclosed
- No Trustpilot footprint at all (owner acknowledges this directly)
- No Finnrick footprint yet (owner reports sending samples for independent testing imminently)
- Blank brand operating roughly one year on DTC; underlying business since late 2024
- Premium pricing per owner's own admission, driven by domestic lyophilization, 3PL fulfillment, and USP-grade API sourcing; among the more expensive options on benchmark compounds
- Owner asserts Zelle "offers the same protection/recourse as any other payment", which overstates Zelle's buyer protections relative to credit-card chargeback rights
- September 2025 MOTS-C fill-volume QC failure (65% labeled potency) is on file as a documented quality incident, even though it was caught before shipment
Vendor facts
Tests reported
Summary
Above-average testing infrastructure for a vendor under two years old: two named labs, universal endotoxin testing, specific per-batch purity values, and a 50-question public transparency Q&A that voluntarily discloses a Sept 2025 batch failure and its corrective action. What is still missing is the breadth of contaminant testing the top vendors publish (heavy metals, sterility, multi-vial conformity), an external validation footprint (no Trustpilot, no Finnrick yet), and full public ownership. The roadmap for closing the testing gap runs through Horizon Analytical; the roadmap for closing the validation gap is just time and posting samples for independent testing.